AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

AbCellera, a privately held biotech company, has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly on the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have the rights to develop and commercialize therapeutic products resulting from the collaboration.

AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly were in discussions about the multi-target agreement in early 2020 when the COVID-19 pandemic emerged. The companies worked quickly to focus the initial scope of the collaboration on creating antibody therapeutics for the possible prevention and treatment of COVID-19. Lilly will select up to eight additional targets during the multi-year agreement.

“Lilly chose to partner with AbCellera because of their novel technology platform, and it has enabled the rapid identification of lead antibody candidates for our COVID-19 efforts. We’re excited to now apply it to other therapeutic targets,” said Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories.

“By working together seamlessly, our teams have moved with unprecedented speed and have advanced from antibody discovery to a lead candidate for human testing in months instead of years,” said Carl Hansen, CEO of AbCellera.

AbCellera's drug discovery platform searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. The company's technology, which combines high-throughput microfluidics, big data, machine learning, bioinformatics, and genomics, identifies new first-in-class drugs and reduces the time it takes to bring treatments to clinic.

Read More

Related news

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

7 Jul 2020

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Read more 
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

7 Jul 2020

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

8 Jun 2020

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more